Literature DB >> 25301559

High expression of ROR2 in cancer cell correlates with unfavorable prognosis in colorectal cancer.

Haijun Mei1, Shuijin Lian2, Shu Zhang2, Wei Wang2, Qinsheng Mao3, Hua Wang4.   

Abstract

The receptor tyrosine kinase-like orphan receptor 2 (ROR2) is a transmembrane protein that belongs to a conserved family of tyrosine kinase receptors involved in several functional processes. ROR2 is overexpressed in various types of solid tumors; however, the expression of ROR2, as well as its functional and prognostic significance has yet to be evaluated in colorectal cancer (CRC). In this study, one-step quantitative reverse transcription-polymerase chain reaction and immunohistochemical analysis using tissue microarrays were used to evaluate ROR2 expression in CRC and to investigate the association between ROR2 expression and patient prognosis. We observed that the expression of ROR2 mRNA and protein was significantly higher in CRC specimens compared with normal, tumor-adjacent tissues (both p<0.05). Cytoplasmic ROR2 expression was related to TNM stage (p=0.041) and lymph node metastasis (N) (p=0.015). Kaplan-Meier and multivariate analyses suggested that high cytoplasmic ROR2 expression (p=0.001), poor tumor differentiation (p=0.001), and advanced TNM stage (p=0.001) and high preoperative CEA level (p<0.001) were significantly associated with unfavorable survival of CRC patients. These results suggest that ROR2 expression is correlated with malignant attributes of CRC and may serve as an indicator for poor prognosis in patients with CRC.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRC; Immunohistochemistry; Prognosis; ROR2; qPCR

Mesh:

Substances:

Year:  2014        PMID: 25301559     DOI: 10.1016/j.bbrc.2014.09.141

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Validation of specificity of antibodies for immunohistochemistry: the case of ROR2.

Authors:  Sean S Q Ma; Claire E Henry; Estelle Llamosas; Rupert Higgins; Benjamin Daniels; Luke B Hesson; Nicholas J Hawkins; Robyn L Ward; Caroline E Ford
Journal:  Virchows Arch       Date:  2016-09-08       Impact factor: 4.064

2.  Up-regulation of ROR2 is associated with unfavorable prognosis and tumor progression in cervical cancer.

Authors:  Bo Sun; Xiufeng Ye; Li Lin; Mei Shen; Taotao Jiang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  The physiological role of Wnt pathway in normal development and cancer.

Authors:  Xiang Li; Maria A Ortiz; Leszek Kotula
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-29

4.  Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer.

Authors:  Liang Feng; Chan Yao; Peng Li; Ying Feng; Fei Wang; Yi-Fei Liu; Yi-Bing Guo; Qin-Sheng Mao; Wan-Jiang Xue
Journal:  Tumour Biol       Date:  2016-01-16

Review 5.  Ror2 as a therapeutic target in cancer.

Authors:  Zufan Debebe; W Kimryn Rathmell
Journal:  Pharmacol Ther       Date:  2015-01-19       Impact factor: 13.400

6.  Expression of Ror2 mediates invasive phenotypes in renal cell carcinoma.

Authors:  Neal R Rasmussen; Zufan Debebe; Tricia M Wright; Samira A Brooks; Adam B Sendor; A Rose Brannon; A Ari Hakimi; James J Hsieh; Toni K Choueiri; Pheroze Tamboli; Jodi K Maranchie; Peter Hinds; Eric M Wallen; Catherine Simpson; Jacqueline L Norris; William P Janzen; W Kimryn Rathmell
Journal:  PLoS One       Date:  2014-12-26       Impact factor: 3.240

7.  Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.

Authors:  C E Henry; C Emmanuel; N Lambie; C Loo; B Kan; C J Kennedy; A de Fazio; N F Hacker; C E Ford
Journal:  Transl Oncol       Date:  2017-03-23       Impact factor: 4.243

8.  RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.

Authors:  Fei Wang; Ying Feng; Peng Li; Kun Wang; Liang Feng; Yi-Fei Liu; Hua Huang; Yi-Bing Guo; Qin-Sheng Mao; Wan-Jiang Xue
Journal:  Oncotarget       Date:  2016-01-26

9.  ROR2 is epigenetically inactivated in the early stages of colorectal neoplasia and is associated with proliferation and migration.

Authors:  Sean S Q Ma; Sameer Srivastava; Estelle Llamosas; Nicholas J Hawkins; Luke B Hesson; Robyn L Ward; Caroline E Ford
Journal:  BMC Cancer       Date:  2016-07-20       Impact factor: 4.430

10.  ROR2 receptor promotes the migration of osteosarcoma cells in response to Wnt5a.

Authors:  Bin Dai; Ting Yan; Ailiang Zhang
Journal:  Cancer Cell Int       Date:  2017-11-29       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.